Cerity Partners LLC Makes New Investment in Abrdn Life Sciences Investors (NYSE:HQL)

Cerity Partners LLC purchased a new position in Abrdn Life Sciences Investors (NYSE:HQL) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 15,608 shares of the company’s stock, valued at approximately $210,000. Cerity Partners LLC owned about 0.06% of Abrdn Life Sciences Investors at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Blue Bell Private Wealth Management LLC increased its stake in Abrdn Life Sciences Investors by 60.4% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 10,125 shares of the company’s stock valued at $136,000 after acquiring an additional 3,811 shares during the last quarter. International Assets Investment Management LLC increased its position in shares of Abrdn Life Sciences Investors by 3,424.5% during the 4th quarter. International Assets Investment Management LLC now owns 11,067 shares of the company’s stock valued at $149,000 after purchasing an additional 10,753 shares during the last quarter. Atlas Wealth LLC lifted its position in Abrdn Life Sciences Investors by 90.7% in the 3rd quarter. Atlas Wealth LLC now owns 24,969 shares of the company’s stock worth $311,000 after buying an additional 11,879 shares during the last quarter. HighTower Advisors LLC bought a new stake in Abrdn Life Sciences Investors in the 3rd quarter worth approximately $394,000. Finally, Private Advisor Group LLC boosted its stake in Abrdn Life Sciences Investors by 78.9% in the third quarter. Private Advisor Group LLC now owns 35,046 shares of the company’s stock worth $435,000 after buying an additional 15,459 shares in the last quarter. Hedge funds and other institutional investors own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Trading Up 1.0 %

HQL opened at $13.10 on Tuesday. Abrdn Life Sciences Investors has a 12 month low of $11.34 and a 12 month high of $14.37. The business’s 50-day moving average price is $13.45 and its 200-day moving average price is $13.12.

Abrdn Life Sciences Investors Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Thursday, February 22nd were given a $0.39 dividend. The ex-dividend date of this dividend was Wednesday, February 21st. This represents a $1.56 annualized dividend and a yield of 11.91%. This is an increase from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.30.

Insider Activity

In other news, major shareholder Saba Capital Management, L.P. bought 120,304 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were bought at an average cost of $13.00 per share, with a total value of $1,563,952.00. Following the completion of the purchase, the insider now directly owns 3,025,602 shares in the company, valued at $39,332,826. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders purchased 224,993 shares of company stock valued at $2,910,910. 10.06% of the stock is currently owned by company insiders.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.